To scan or not to scan : Use of transient elastography in an integrated health system
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved..
BACKGROUND: Non-invasive tests, such as Fibrosis-4 index and transient elastography (commonly FibroScan), are utilized in clinical pathways to risk stratify and diagnose non-alcoholic fatty liver disease (NAFLD). In 2018, a clinical decision support tool (CDST) was implemented to guide primary care providers (PCPs) on use of FibroScan for NAFLD.
AIM: To analyze how this CDST impacted health care utilization and patient outcomes.
METHODS: We performed a retrospective review of adults who had FibroScan for NAFLD indication from January 2015 to December 2017 (pre-CDST) or January 2018 to December 2020 (post-CDST). Outcomes included FibroScan result, laboratory tests, imaging studies, specialty referral, patient morbidity and mortality.
RESULTS: We identified 958 patients who had FibroScan, 115 before and 843 after the CDST was implemented. The percentage of FibroScans ordered by PCPs increased from 33% to 67.1%. The percentage of patients diagnosed with early F1 fibrosis, on a scale from F0 to F4, increased from 7.8% to 14.2%. Those diagnosed with advanced F4 fibrosis decreased from 28.7% to 16.5%. There were fewer laboratory tests, imaging studies and biopsy after the CDST was implemented. Though there were more specialty referrals placed after the CDST was implemented, multivariate analysis revealed that healthcare utilization aligned with fibrosis score, whereby patients with more advanced disease had more referrals. Very few patients were hospitalized or died.
CONCLUSION: This CDST empowered PCPs to diagnose and manage patients with NAFLD with appropriate allocation of care towards patients with more advanced disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
World journal of hepatology - 15(2023), 3 vom: 27. März, Seite 419-430 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stein, Libby [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical decision support tool |
|---|
| Anmerkungen: |
Date Revised 11.04.2023 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4254/wjh.v15.i3.419 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355388642 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355388642 | ||
| 003 | DE-627 | ||
| 005 | 20231226064236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4254/wjh.v15.i3.419 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355388642 | ||
| 035 | |a (NLM)37034236 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stein, Libby |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a To scan or not to scan |b Use of transient elastography in an integrated health system |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.04.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Non-invasive tests, such as Fibrosis-4 index and transient elastography (commonly FibroScan), are utilized in clinical pathways to risk stratify and diagnose non-alcoholic fatty liver disease (NAFLD). In 2018, a clinical decision support tool (CDST) was implemented to guide primary care providers (PCPs) on use of FibroScan for NAFLD | ||
| 520 | |a AIM: To analyze how this CDST impacted health care utilization and patient outcomes | ||
| 520 | |a METHODS: We performed a retrospective review of adults who had FibroScan for NAFLD indication from January 2015 to December 2017 (pre-CDST) or January 2018 to December 2020 (post-CDST). Outcomes included FibroScan result, laboratory tests, imaging studies, specialty referral, patient morbidity and mortality | ||
| 520 | |a RESULTS: We identified 958 patients who had FibroScan, 115 before and 843 after the CDST was implemented. The percentage of FibroScans ordered by PCPs increased from 33% to 67.1%. The percentage of patients diagnosed with early F1 fibrosis, on a scale from F0 to F4, increased from 7.8% to 14.2%. Those diagnosed with advanced F4 fibrosis decreased from 28.7% to 16.5%. There were fewer laboratory tests, imaging studies and biopsy after the CDST was implemented. Though there were more specialty referrals placed after the CDST was implemented, multivariate analysis revealed that healthcare utilization aligned with fibrosis score, whereby patients with more advanced disease had more referrals. Very few patients were hospitalized or died | ||
| 520 | |a CONCLUSION: This CDST empowered PCPs to diagnose and manage patients with NAFLD with appropriate allocation of care towards patients with more advanced disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical decision support tool | |
| 650 | 4 | |a FibroScan | |
| 650 | 4 | |a Health care utilization | |
| 650 | 4 | |a Non-alcoholic fatty liver disease | |
| 650 | 4 | |a Primary care | |
| 650 | 4 | |a Transient elastography | |
| 700 | 1 | |a Mittal, Rasham |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Hubert |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Joanie |e verfasserin |4 aut | |
| 700 | 1 | |a Sahota, Amandeep |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of hepatology |d 2009 |g 15(2023), 3 vom: 27. März, Seite 419-430 |w (DE-627)NLM204379024 |x 1948-5182 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:3 |g day:27 |g month:03 |g pages:419-430 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4254/wjh.v15.i3.419 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 3 |b 27 |c 03 |h 419-430 | ||